AAP
SION

Arax Advisory Partners’s Sionna Therapeutics SION Stock Holding History

Arax Advisory Partners’s Portfolio SION Stock Details SION Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-92
Closed -$2.71K – 4622
2025
Q3 		$2.71K Buy
+92
New +$2K ﹤0.01% 3035

Other funds holding SION

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Arax Advisory Partners's SION Position: Q4 2025 in Review

Arax Advisory Partners sold out of Sionna Therapeutics (SION) in Q4 2025, closing a stake of 92 shares — an estimated $2.71K sold.

Arax Advisory Partners first reported a position in SION in Q3 2025 and held it in 1 quarter. The position peaked at $2.71K in Q3 2025. 101 funds tracked by Wall St. Rank hold SION as of Q4 2025.

  • Arax Advisory Partners reported no remaining Sionna Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Arax Advisory Partners sold 92 Sionna Therapeutics shares in Q4 2025, an estimated $2.71K.
  • Arax Advisory Partners first reported a position in Sionna Therapeutics in Q3 2025 and held it in 1 quarter.
  • Arax Advisory Partners's Sionna Therapeutics position peaked at $2.71K in Q3 2025.
  • 101 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q4 2025.

Based on Arax Advisory Partners's 13F filing for Q4 2025, filed 13 Feb 2026.